A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus

BMC Ophthalmology

Volumn 12, Issue 1, 2012, Pages

  Dombi, Theresa ^a   Kwok, Kenneth K ^a   Sultan, Marla B ^a,b  

^a PFIZER INC   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; PEGAPTANIB; VASCULOTROPIN A;

ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOSE RESPONSE; DRUG ANTAGONISM; FOLLOW UP; HUMAN; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME;

APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; CROSS-OVER STUDIES; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864532015     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-12-37     Document Type: Article

References (30)

1. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Adamis AP, Berman AJ, Semin Immunopathol 2008 30 2 65 84 10.1007/s00281-008- 0111-x 18340447
2. Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches. Gardner TW, Antonetti DA, Curr Diab Rep 2008 8 4 263 269 10.1007/s11892-008-0047-5 18631437
3. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Kern TS, Exp Diabetes Res 2007 2007 95103 18274606
4. Vascular endothelial growth factor and diabetic complications. Wirostko B, Wong TY, Simo R, Prog Retin Eye Res 2008 27 6 608 621 10.1016/j.preteyeres. 2008.09.002 18929676
5. Use of antivascular endothelial growth factor for diabetic macular edema. Karim R, Tang B, Clin Ophthalmol 2010 4 493 517 20535227
6. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Nicholson BP, Schachat AP, Graefes Arch Clin Exp Ophthalmol 2010 248 7 915 930 10.1007/s00417-010-1315-z 20174816
7. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Querques G, Bux AV, Martinelli D, Iaculli C, Noci ND, Acta Ophthalmol 2009 87 6 623 630 10.1111/j.1755-3768.2009.01580.x 19678810
8. Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema. Querques G, Bux AV, Fusco AR, Iaculli C, Delle Noci N, J Ophthalmol 2009 2009 672178 20339449
9. Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy. Hornan D, Edmeades N, Krishnan R, Khan J, Lochhead J, Eye (Lond) 2010 24 8 1315 1319 10.1038/eye.2010.14
10. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, et al. Circulation 2008 117 15 1945 1954 10.1161/CIRCULATIONAHA.107.720847 18378618
11. Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Alegiani SS, Raschetti R, Velussi M, Ferrannini E, Stroke 2007 38 4 1154 1160 10.1161/01.STR.0000260100.71665.2f 17332448
12. The impact of diabetes on coronary heart disease differs from that on ischaemic stroke with regard to the gender. Hyvarinen M, Tuomilehto J, Laatikainen T, Soderberg S, Eliasson M, Nilsson P, Qiao Q, Cardiovasc Diabetol 2009 8 17 10.1186/1475-2840-8-17 19317900
13. Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: a population-based cohort study. Jeerakathil T, Johnson JA, Simpson SH, Majumdar SR, Stroke 2007 38 6 1739 1743 10.1161/STROKEAHA.106.481390 17478738
14. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al. Lancet 2010 375 9733 2215 2222 10.1016/S0140-6736(10)60484-9 20609967
15. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M, N Engl J Med 1998 339 4 229 234 10.1056/NEJM199807233390404 9673301
16. Peripheral arterial disease in people with diabetes. Diabetes Care 2003 26 12 3333 3341 14633825
17. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B, Ophthalmology 2006 113 6 992 1001 e1006 10.1016/j.ophtha.2006.02.027 16647134
18. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D, Br J Ophthalmol 2008 92 12 1606 1611 10.1136/bjo.2007.132597 18614570
19. Pegaptanib sodium for the treatment of age-related macular degeneration. Apte RS, Expert Opin Pharmacother 2008 9 3 499 508 10.1517/14656566.9.3.499 18220500
20. Pegaptanib for neovascular age-related macular degeneration. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, N Engl J Med 2004 351 27 2805 2816 10.1056/NEJMoa042760 15625332
21. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J (Clin Res Ed) 1988 296 6618 320 331
22. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994 308 6921 81 106 8298418
23. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Kamba T, McDonald DM, Br J Cancer 2007 96 12 1788 1795 10.1038/sj.bjc.6603813 17519900
24. Cerebrovascular accidents in ranibizumab. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T, Ophthalmology 2009 116 2 362 19187827
25. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, Lelgemann M, Br J Ophthalmol 2011 95 3 308 317 10.1136/bjo.2009.178574 20971791
26. Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database. Micieli JA, Micieli A, Smith AF, Can J Ophthalmol 2010 45 3 231 238 10.3129/i10-027 20628421
27. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M, Curr Opin Ophthalmol 2010 21 3 218 226 10.1097/ICU.0b013e3283386783 20393293
28. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T, Br J Ophthalmol 2010 94 9 1215 1218 10.1136/bjo.2008.156810 20538658
29. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP, Ophthalmology 2007 114 9 1702 1712 17509689
30. Long Term Efficacy and Safety Profile of Pegaptanib Sodium for Age-related Macular Degeneration with Choroidal Neovascularization-Evaluation of Extended Phase II Clinical Trial. Ishibashi T, Nippon Ganka Gakkai Zasshi 2011 115 2 122 133 21400918